TopoTarget Announces New Preclinical Results with Belinostat to be presented at AACR Annual Meeting

To the Copenhagen Stock Exchange
Announcement No. 10-07 / Copenhagen 12 April 2007
 

TopoTarget Announces New Preclinical Results with Belinostat to be presented at
AACR Annual Meeting 
			
Copenhagen, 12 April 2007, TopoTarget A/S (CSE:TOPO) announced today that new
preclinical data on belinostat (PXD101), a histone deacetylase (HDAC) inhibitor
being investigated for the treatment of cancer, will be presented at the
upcoming American Association for Cancer Research (AACR) 2007 Annual Meeting in
Los Angeles, April 14-18, 2007.  A total of five poster presentations on
belinostat (PXD101) will be made during the conference. 

Belinostat (PXD101), HDAC inhibitor for the treatment of cancer:

- “Activity of PXD101, an HDAC inhibitor, used alone or in combination with
5-FU in preclinical gastroesophageal studies,” (Abstract #691) during the
conference's HDAC Inhibitors I poster session on Sunday, April 15th in the
Exhibit Hall on Poster Board #14 

- “Gene expression screen in cell panel selected for varying sensitivity
towards the Histone Deacetylase inhibitor (HDACi) PXD101 reveals potential
predictors of HDACi sensitivity,” (Abstract #687) during the conference's HDAC
Inhibitors I poster session on Sunday, April 15th in the Exhibit Hall on Poster
Board #10 

- “The effect of the histone deacetylase inhibitor (HDACi) PXD101 on cell
growth and expression of viral and host genes in hepatitis B virus
(HBV)-carrying hepatocellular carcinoma (HCC) cell lines,” (Abstract #696)
during the conference's HDAC Inhibitors I poster session on Sunday, April 15th
in the Exhibit Hall on Poster Board #19 

-“The histone deacetylase (HDAC) inhibitor PXD101 suppresses bladder cancer
cell growth both in-vitro and in-vivo,” (Abstract #2211) during the
conference's Mouse Models of Cancer 2: Therapeutic Approaches poster session on
Monday, April 16th on Poster Board #9 

- “The HDAC inhibitors romidepsin and PXD101 interact synergistically with
Bortezomib in human chronic lymphocytic leukemia (CLL) cells in association
with NF-κB inactivation,” (Abstract #1835) during the conference's Targeted
Agents and Other Novel Therapies poster session on Monday, April 16th on Poster
Board #21 

 
TopoTarget A/S

For further information, please contact:

Dr. Peter Buhl Jensen		Telephone	+45 39 17 83 41
Chief Executive Officer		Mobile	+45 21 60 89 22


Background information

About Belinostat (PXD101)
Belinostat is a promising small molecule HDAC inhibitor being investigated for
its role in the treatment of a wide range of solid and hematologic malignancies
either as a single-agent, or in combination with other active anti-cancer
agents, including 5-FU, car-boplatin, paclitaxel, cis-retinoic acid,
azacitidine and Velcade® (bortezomib) for Injec-tion.  HDAC inhibitors
represent a new mechanistic class of anti-cancer therapeutics that target HDAC
enzymes and have been shown to: arrest growth of cancer cells (in-cluding drug
resistant subtypes); induce apoptosis, or programmed cell death; promote
differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome
drug resis-tance when used in combination with other anti-cancer agents. 

Intravenous belinostat is currently being evaluated in multiple clinical trials
as a poten-tial treatment for multiple myeloma, T- and B-cell lymphomas, AML,
mesothelioma, liver, colorectal, ovarian cancers, either alone or in
combination with anti-cancer thera-pies.  An oral formulation of belinostat is
also being evaluated in a Phase I clinical trial for patients with advanced
solid tumors.  In August 2004, CuraGen signed a Clinical Trials Agreement with
the NCI under which the NCI will sponsor several clinical trials to investigate
belinostat for the treatment of various cancers, both as a single-agent and in
combination chemotherapy regimens.  In May 2005, TopoTarget announced the
signing of a Cooperative Research and Development Agreement (CRADA) with the
NCI to conduct preclinical and nonclinical studies on belinostat in order to
better understand its anti-tumor activity and to provide supporting information
for clinical trials. 

About TopoTarget
TopoTarget (OMX - The Nordic Exchange: TOPO) is a biopharmaceutical company,
headquartered in Denmark and with subsidiaries in the UK, Germany and the USA,
dedicated to finding ''Answers for Cancer'' and developing improved cancer
therapies. TopoTarget is founded and run by clinical cancer specialists and
combines years of hands-on clinical experience with in-depth understanding of
the molecular mechanisms of cancer. Focus lies on highly predictive cancer
models and key cancer enzyme regula-tors (mainly HDAC, mTOR, and topoisomerase
II inhibitors) and a strong development foundation has been built. TopoTarget
has a broad portfolio of small molecule preclini-cal drug candidates and seven
drugs are in clinical development, including both novel anti-cancer
therapeutics and new cancer indications for existing drugs. Savene™ is
TopoTarget's first product on the market. In addition to organic growth,
TopoTarget consistently looks for opportunities to strengthen and expand its
activities through acquisitions and in-licensing. For more information, please
refer to Hwww.topotarget.com.H 

TopoTarget Safe Harbour Statement
This announcement may contain forward-looking statements, including statements
about our expectations of the progression of our preclinical and clinical
pipeline includ-ing the timing for commencement and completion of clinical
trials and with respect to cash burn guidance.  Such statements are based on
management's current expecta-tions and are subject to a number of risks and
uncertainties that could cause actual results to differ materially from those
described in the forward-looking statements.  TopoTarget cautions investors
that there can be no assurance that actual results or business conditions will
not differ materially from those projected or suggested in such forward-looking
statements as a result of various factors, including, but not limited to, the
following: the risk that any one or more of the drug development programs of
TopoTarget will not proceed as planned for technical, scientific or commercial
reasons or due to patient enrolment issues or based on new information from
nonclinical or clinical studies or from other sources; the success of competing
products and technolo-gies; technological uncertainty and product development
risks;  uncertainty of addi-tional funding; TopoTarget's history of incurring
losses and the uncertainty of achieving profitability; TopoTarget's stage of
development as a biopharmaceutical company; government regulation; patent
infringement claims against TopoTarget's products, processes and technologies;
the ability to protect TopoTarget's patents and proprietary rights;
uncertainties relating to commercialization rights; and product liability
expo-sure; We disclaim any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events, or otherwise, unless required by law.